Albany Molecular Research, Inc. (NASDAQ:AMRI) SVP Steven R. Hagen sold 785 shares of the stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $16.79, for a total transaction of $13,180.15. Following the completion of the sale, the senior vice president now directly owns 34,913 shares in the company, valued at $586,189.27. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) opened at 17.41 on Tuesday. Albany Molecular Research, Inc. has a 52-week low of $12.45 and a 52-week high of $20.65. The company has a 50-day moving average of $16.33 and a 200-day moving average of $14.92. The stock’s market capitalization is $724.08 million.

Albany Molecular Research (NASDAQ:AMRI) last announced its earnings results on Tuesday, November 8th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.04. Albany Molecular Research had a negative net margin of 10.48% and a positive return on equity of 7.25%. The business had revenue of $151.70 million for the quarter, compared to analyst estimates of $160.75 million. During the same quarter last year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 45.0% compared to the same quarter last year. Equities research analysts anticipate that Albany Molecular Research, Inc. will post $1.08 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Moody Aldrich Partners LLC raised its stake in shares of Albany Molecular Research by 169.3% in the second quarter. Moody Aldrich Partners LLC now owns 125,257 shares of the company’s stock valued at $1,683,000 after buying an additional 78,752 shares during the period. Strs Ohio raised its stake in shares of Albany Molecular Research by 32.0% in the second quarter. Strs Ohio now owns 47,400 shares of the company’s stock valued at $637,000 after buying an additional 11,500 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Albany Molecular Research by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the company’s stock valued at $161,000 after buying an additional 100 shares during the period. Bank of Montreal Can bought a new stake in shares of Albany Molecular Research during the second quarter valued at about $7,777,000. Finally, AMI Asset Management Corp raised its stake in shares of Albany Molecular Research by 55.6% in the second quarter. AMI Asset Management Corp now owns 876,443 shares of the company’s stock valued at $11,779,000 after buying an additional 313,225 shares during the period. Institutional investors and hedge funds own 74.30% of the company’s stock.

Separately, Morgan Stanley reissued a “buy” rating and issued a $17.00 price objective on shares of Albany Molecular Research in a research report on Friday, August 5th.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Receive News & Stock Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related stocks with our FREE daily email newsletter.